ArticleWorld journal of plastic surgery2025
Comparing the Effects of Mitomycin-C and Triamcinolone-Acetonide Injections on Hypertrophic Scars and Keloids in Burn Patients.
Article in World journal of plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertrophic scars (HTS) and keloids are the proliferative responses of the fibroblastic. Surgical excision lead to changes, but postoperative recurrence rate seems to be still high. The topical use of mitomycin C (MMC) has been thus documented to suppress fibroblast proliferation. We aimed to investigate the effects of MMC injection on HTS and keloids in burn wounds, and compare the results with intralesional Triamcinolone Acetonide (TAC) injection in with regard to scar size reduction. Methods: This randomized clinical trial was conducted on 90 burn patients (divided into two groups) with hypertrophic scars and keloids at Taleghani Burn Hospital, Ahvaz, Iran, in 2023. Patients were randomly assigned to receive intralesional MMC (0.4 mg/dL) or TAC (0.4 mg/dL). Scar characteristics were assessed pre- and post-treatment using the Vancouver Scar Scale (VSS) over six months. Results: The average size of the scars at the pre- and post-intervention stages was 15.71 and 4.81 mm. No significant difference was observed between both groups. Effect of MMC was over and above TAC. There was a significant difference between both groups. Significant difference was found between the Vancouver Scar Scale (VSS) mean scores before and after the intervention, so the TAC value was greater than that of MMC, and the scores at the pre- and post-intervention stages were significantly different. Conclusion: MMC and TAC were considered as effective methods for HTS and keloid management. In spite of this, the VSS scores and the scar size denoted that MMC was much more effective in the treatment of such scars than TAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.